This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shulby, S. A. Articles by Fatatis, A. Search for Related Content PubMed PubMed Citation Articles by Shulby, S. A. Articles by Fatatis, A.

CX3CR1-Fractalkine Expression Regulates Cellular Mechanisms Involved in Adhesion, Migration, and Survival of Human Prostate Cancer Cells

Departments of ¹ Pharmacology and Physiology and ² Pathology, Drexel University, College of Medicine, Philadelphia, Pennsylvania

Chemokines and their receptors might be involved in the selection of specific organs by metastatic cancer cells. For instance, the CXCR4-SDF-1 pair regulates adhesion and migration of breast as well as prostate cancer cells to metastatic sites. In this study, we present the first evidence for the expression of CX3CR1—the specific receptor for the chemokine fractalkine—by human prostate cancer cells, whereas human bone marrow endothelial cells and differentiated osteoblasts express fractalkine. The adhesion of prostate cancer cells to human bone marrow endothelial cells in flow conditions is significantly reduced by a neutralizing antibody against fractalkine, and they migrate toward a medium conditioned by osteoblasts, which secrete the soluble form of the chemokine. Finally, fractalkine activates the PI3K/Akt survival pathway in human prostate cancer cells.

This article has been cited by other articles:

				D. Vindrieux, P. Escobar, and G. Lazennec Emerging roles of chemokines in prostate cancer Endocr. Relat. Cancer, September 1, 2009; 16(3): 663 - 673. [Abstract] [Full Text] [PDF]

				C. Auffray, D. K. Fogg, E. Narni-Mancinelli, B. Senechal, C. Trouillet, N. Saederup, J. Leemput, K. Bigot, L. Campisi, M. Abitbol, et al. CX3CR1+ CD115+ CD135+ common macrophage/DC precursors and the role of CX3CR1 in their response to inflammation J. Exp. Med., March 16, 2009; 206(3): 595 - 606. [Abstract] [Full Text] [PDF]

				D. Castellana, F. Zobairi, M. C. Martinez, M. A. Panaro, V. Mitolo, J.-M. Freyssinet, and C. Kunzelmann Membrane Microvesicles as Actors in the Establishment of a Favorable Prostatic Tumoral Niche: A Role for Activated Fibroblasts and CX3CL1-CX3CR1 Axis Cancer Res., February 1, 2009; 69(3): 785 - 793. [Abstract] [Full Text] [PDF]

				D. L. Blum, T. Koyama, A. E. M'Koma, J. M. Iturregui, M. Martinez-Ferrer, C. Uwamariya, J. A. Smith Jr., P. E. Clark, and N. A. Bhowmick Chemokine Markers Predict Biochemical Recurrence of Prostate Cancer following Prostatectomy Clin. Cancer Res., December 1, 2008; 14(23): 7790 - 7797. [Abstract] [Full Text] [PDF]

				F. Marchesi, L. Piemonti, G. Fedele, A. Destro, M. Roncalli, L. Albarello, C. Doglioni, A. Anselmo, A. Doni, P. Bianchi, et al. The Chemokine Receptor CX3CR1 Is Involved in the Neural Tropism and Malignant Behavior of Pancreatic Ductal Adenocarcinoma Cancer Res., November 1, 2008; 68(21): 9060 - 9069. [Abstract] [Full Text] [PDF]

				Y. Lu, J. Wang, Y. Xu, A. E. Koch, Z. Cai, X. Chen, D. L. Galson, R. S. Taichman, and J. Zhang CXCL16 Functions as a Novel Chemotactic Factor for Prostate Cancer Cells In vitro Mol. Cancer Res., April 1, 2008; 6(4): 546 - 554. [Abstract] [Full Text] [PDF]

				W. L. Jamieson, S. Shimizu, J. A. D'Ambrosio, O. Meucci, and A. Fatatis CX3CR1 Is Expressed by Prostate Epithelial Cells and Androgens Regulate the Levels of CX3CL1/Fractalkine in the Bone Marrow: Potential Role in Prostate Cancer Bone Tropism Cancer Res., March 15, 2008; 68(6): 1715 - 1722. [Abstract] [Full Text] [PDF]

				N. G. Dolloff, M. R. Russell, N. Loizos, and A. Fatatis Human Bone Marrow Activates the Akt Pathway in Metastatic Prostate Cells through Transactivation of the {alpha}-Platelet-Derived Growth Factor Receptor Cancer Res., January 15, 2007; 67(2): 555 - 562. [Abstract] [Full Text] [PDF]

				P. Liu, S. Patil, M. Rojas, A. M. Fong, S. S. Smyth, and D. D. Patel CX3CR1 Deficiency Confers Protection From Intimal Hyperplasia After Arterial Injury Arterioscler Thromb Vasc Biol, September 1, 2006; 26(9): 2056 - 2062. [Abstract] [Full Text] [PDF]

				K. S. R. Sastry, A. J. Smith, Y. Karpova, S. R. Datta, and G. Kulik Diverse Antiapoptotic Signaling Pathways Activated by Vasoactive Intestinal Polypeptide, Epidermal Growth Factor, and Phosphatidylinositol 3-Kinase in Prostate Cancer Cells Converge on BAD J. Biol. Chem., July 28, 2006; 281(30): 20891 - 20901. [Abstract] [Full Text] [PDF]

				F. Andre, N. Cabioglu, H. Assi, J. C. Sabourin, S. Delaloge, A. Sahin, K. Broglio, J. P. Spano, C. Combadiere, C. Bucana, et al. Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer Ann. Onc., June 1, 2006; 17(6): 945 - 951. [Abstract] [Full Text] [PDF]

				J.-W. Kim, R. L. Ferris, and T. L. Whiteside Chemokine C Receptor 7 Expression and Protection of Circulating CD8+ T Lymphocytes from Apoptosis Clin. Cancer Res., November 1, 2005; 11(21): 7901 - 7910. [Abstract] [Full Text] [PDF]

				J.-C. Gevrey, B. M. Isaac, and D. Cox Syk Is Required for Monocyte/Macrophage Chemotaxis to CX3CL1 (Fractalkine) J. Immunol., September 15, 2005; 175(6): 3737 - 3745. [Abstract] [Full Text] [PDF]